ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 575

Facet Joint Ankylosis on Whole Spine Low-Dose CT in Radiographic Axial Spondyloarthritis

Rosalinde Stal1, Floris van Gaalen 1, Alexandre Sepriano 1, Jürgen Braun 2, Monique Reijnierse 1, Désirée van der Heijde 1 and Xenofon Baraliakos 3, 1Leiden University Medical Center, Leiden, Netherlands, 2Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany, 3Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: spondylarthritis and Imaging

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In radiographic axial spondyloarthritis (r-axSpA), whole spine low-dose CT (ldCT) is superior to conventional radiography (CR) in detecting syndesmophytes, mainly due to inclusion of the thoracic spine. Facet joint ankylosis has been studied in r-axSpA in parts of the spine with CR and CT, but not in the whole spine. We aimed to assess readability and interreader reliability of facet joint ankylosis as detected by whole spine ldCT and to describe the prevalence of facet joint ankylosis in each spinal segment in patients with r-axSpA.

Methods: In an observational cohort, r-axSpA patients with syndesmophytes on at least one but no more than 75% of spinal levels of the cervical and lumbar segments on CR and at least one inflammatory lesion on spinal MRI, underwent ldCT (about 4 mSv) of the whole spine. Images were assessed independently by two trained readers and left and right C2-C3 to L5-S1 facet joints were scored as ankylosis present (1) or absent (0). The percentage of missing joint scores due to inability to assess, were calculated per reader and joint level. Joint levels with >15% missing joint scores for ≥1 reader were deemed unreliable to score and were excluded from the study. Interreader reliability was assessed by calculating intraclass correlation coefficients (ICCs), two-way average, absolute agreement. Ankylosis scores were summed per patient per segment and for the whole spine and presented as mean scores per reader. The percentage of patients with an ankylosed joint were presented per joint level in a heatmap.

Results: A total of 60 r-axSpA patients were analyzed (mean age 47.7 years, 85% male, 80% HLA-B27+). Reader 1 had between 0% and 18% missing scores per joint, reader 2 had between 0% and 52% missing scores per joint (figure 1). There were >15% missing joint scores for ≥1 reader on levels C5-T2, which were excluded from analyses. Interreader reliability was good to excellent with ICCs ranging from 0.81 to 0.93 (table). Ankylosis occurred at every joint level, but was most prevalent in the thoracic spine (figure 2). Means (SD) of sum-scores for the whole spine and cervical, thoracic and lumbar segments for both readers are presented in the Table.

Conclusion: Facet joints around the cervicothoracic junction were difficult to score in a relatively high percentage of patients and are therefore excluded from scoring. The interreader reliability of the remaining levels was good to excellent. In patients with r-axSpA and at least one syndesmophyte, facet joint ankylosis was detected in all spinal levels, but most ankylosis occurred in the thoracic spine. These results show that ldCT can be used to study facet joint ankylosis in r-axSpA in all spinal segments except the cervicothoracic junction.


Disclosure: R. Stal, None; F. van Gaalen, None; A. Sepriano, None; J. Braun, Abbott, 2, 5, AbbVie, 2, 5, 6, 8, Amgen, 2, 5, 8, Baxter, 2, 5, 8, Biogen, 2, 8, 9, BMS, 2, 5, 8, Boehringer, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Celgene, 2, 3, 5, 8, Celltrion, 2, 5, 8, Centocor, 2, 5, 8, Chugai, 2, 5, 8, Eli Lilly and Company, 2, 5, 8, Hexal, 2, 5, 8, Janssen, 2, 5, 8, Johnson & Johnson, 2, 5, Medac, 2, 5, 8, MSD, 2, 5, MSD (Schering-Plough), 2, 5, 8, Mundipharma, 2, 5, 8, Mylan, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, Pfizer (Wyeth, Hospira), 2, 5, 8, Roche, 2, 5, 8, Sanofi-Aventis, 2, 5, 8, UCB Pharma, 2, 5, 8; M. Reijnierse, None; D. van der Heijde, AbbVie, 5, AbbVie, Amgen, Astellas, AstraZeneca, BMS, 5, Amgen, 5, Astellas, 5, 9, Astellas Pharma, 5, AstraZeneca, 5, BMS, 5, Boehringer Ingelheim, 5, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, GSK, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squibb, 5, Celgene, 5, Daiichi, 5, 9, Daiichi Sankyo, 5, Director of Imaging Rheumatology, 6, Director of Imaging Rheumatology bv, 9, Eli Lilly, 5, Eli Lilly and Company, 5, Eli-Lilly, 5, Galapagos, 5, Gilead, 5, Gilead Sciences, Inc., 5, GlaxoSmithKline, 5, Glaxo-Smith-Kline, 5, GSK, 5, 8, Imaging Rheumatology bv, 9, Imaging Rheumatology BV, 9, Imaging Rheumatology bv., 9, Janssen, 5, 8, Janssen Pharmaceutica, 5, Merck, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Pfizer Inc, 5, Regeneron, 5, 8, Rheumatology bv, 4, 9, Roche, 5, 8, Sanofi, 5, 8, Takeda, 5, 8, Takeda Pharmaceutical Company, 5, UCB, 5, 8, UCB Pharma, 5; X. Baraliakos, AbbVie, 2, 5, 8, Abbvie, 2, 5, 8, BMS, 2, 5, 8, 9, Bristol-Myers Squibb, 2, 5, 8, Celgene, 2, 5, 8, 9, Chugai, 2, 5, 8, 9, Janssen, 2, 5, 8, 9, Lilly, 2, 8, 9, Merck, 2, 5, 8, MSD, 2, 5, 8, 9, Novartis, 2, 5, 8, 9, Novatis, 2, 5, 8, Pfizer, 2, 5, 8, 9, UCB, 2, 5, 8, 9, UCB Pharma, 2, 5, 8, Werfen, 2, 5, 8.

To cite this abstract in AMA style:

Stal R, van Gaalen F, Sepriano A, Braun J, Reijnierse M, van der Heijde D, Baraliakos X. Facet Joint Ankylosis on Whole Spine Low-Dose CT in Radiographic Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/facet-joint-ankylosis-on-whole-spine-low-dose-ct-in-radiographic-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/facet-joint-ankylosis-on-whole-spine-low-dose-ct-in-radiographic-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology